Does the Presence of Ductal Carcinoma in situ Affect Prognostic Outcomes After Neoadjuvant Therapy in Invasive Ductal Carcinoma of the Breast?

Suming Zhou, Yuhua Shi, Zhen Huang, 要子 伊藤, Wei XingClinical 2025 · DOI

Abstract

The presence of DCIS in IDC demonstrated less tumour aggressiveness than pure IDC. However, a survival benefit was only observed in patients with triple-negative IDC combined with DCIS after NAT. Furthermore, patients with IDC + DCIS have a higher risk of residual DCIS after NAT, and age <40 years and the luminal subtype are risk factors for residual DCIS after NAT in patients with IDC + DCIS.
BibTeX
@inproceedings{zhou2025does,
  author = {Suming Zhou and Yuhua Shi and Zhen Huang and 要子 伊藤 and Wei Xing},
  title = {{Does the Presence of Ductal Carcinoma in situ Affect Prognostic Outcomes After Neoadjuvant Therapy in Invasive Ductal Carcinoma of the Breast?}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1016/j.clon.2025.103781},
}

Loading related content...

Figure